Performance of 4 Immunohistochemical Phosphohistone H3 Antibodies for Marking Mitotic Figures in Breast Cancer
Background: Phosphohistone H3 (PHH3) has been suggested to facilitate and improve mitotic activity assessment in breast cancer and other tumor entities, but the reliability of respective immunohistochemical antibodies has not yet been compared for routine purposes. Our aim was to test the performance of 4 different PHH3 antibodies on a series of highly proliferating breast cancers with good preservation of morphology. Methods: Four commercially available PHH3 antibodies were tested on 9 grade 3 invasive breast cancers processed in the same batch. We analyzed the number of antibody stained and nonstained mitotic figures as well as the total of cells observed in 10 high power fields per tumor to calculate sensitivity, specificity, and accuracy of the respective antibodies for staining mitotic figures, taking morphologically defined mitotic figures as gold standard. Results: Sensitivity, specificity, and accuracy of the respective PHH3 antibodies for staining mitotic figures were 54.51%, 99.98%, and 98.79% for Cell Marque, 87.48%, 67.62%, and 67.47% for Epitomics, 98.62%, 99.73%, and 99.49% for Merck 06-570, and 99.74%, 99.52%, and 99.51% for Merck 09-797, respectively. Sensitivity was lowest for telophase. In statistical analysis, the Cell Marque antibody demonstrated significantly lower sensitivity and Epitomics substantially lower sensitivity and specificity than Merck 06-570 and Merck 09-797 antibodies (P
Ken and Jane Gremling have shared everything since they got married in 1971, just three weeks after they started dating. But they never expected to receive identical breast cancer diagnoses.
In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy.
Two biology researchers from Georgia State University describe the racial gap, why it eludes scientists, and what we are learning about how to close the gap.
Publication date: Available online 18 October 2018Source: Stem Cell ReportsAuthor(s): Leonor Lopez Almeida, Michael Sebbagh, François Bertucci, Pascal Finetti, Julien Wicinski, Sylvie Marchetto, Rémy Castellano, Emmanuelle Josselin, Emmanuelle Charafe-Jauffret, Christophe Ginestier, Jean-Paul Borg, Marie-Josée SantoniSummaryTumor initiation, progression, and therapeutic resistance have been proposed to originate from a subset of tumor cells, cancer stem cells (CSCs). However, the current understanding of the mechanisms involved in their self-renewal and tumor initiation capacity remains limited. Here, ...
Condition: Breast Cancer Intervention: Behavioral: Lifestyle alteration Sponsor: Hospices Civils de Lyon Recruiting
Conditions: Breast Cancer; Acute Pain; Anesthesia Interventions: Procedure: PVB group; Procedure: MTP block group; Procedure: Control Group Sponsor: Ottawa Hospital Research Institute Not yet recruiting
Condition: Breast Cancer Intervention: Drug: Caelyx® Sponsors: European Institute of Oncology; Janssen-Cilag International NV Recruiting
Condition: Breast Cancer Intervention: Device: Macrodyne LivMD plate Sponsor: Indiana University Not yet recruiting
More than 55,000 women in the UK are diagnosed with breast cancer each year, which equates to a staggering 1 in 8 women being diagnosed at some stage... The post Our Macclesfield office holds a Pink Party in aid of breast cancer appeared first on Ashfield Healthcare.
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 -- (Healthcare Sales &Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for... Biopharmaceuticals, Generics, Oncology, Regulatory Mylan, Biocon, Ogivri, Herceptin, trastuzumab, breast cancer, biosimilar